Tharcila Chaves

tharcila.chaves-150 ist Pharmazeutin mit einem Masterabschluss in Medizin und Soziologie des Drogenmissbrauchs. Im Rahmen ihrer Master-Studie führte sie qualitative Forschungen durch, in welchen das Craving bei Crack-Kokain Konsumenten in der Stadt Sao Paolo untersucht wurde. Außerdem arbeitete sie als Lehrerin im Regenwald am Amazonas, wo sie Medizin, Pharmazie und Krankenpflege in Abschlussklassen unterrichtete. Derzeit lebt sie in Groningen, Niederlande, wo sie im Rahmen ihrer Doktorarbeit die Verwendung von Ketamin zur Behandlung von Depressionen untersucht und klinische Versuchsreihen mit depressiven Patienten plant.

talk 2016 : Oral ketamine for the treatment of pain
and treatment-resistant depression     ( Sprache Englisch )

Background
Recent studies with intravenous (i.v.) application of ketamine show remarkable but short-term success in patients with MDD. Studies in patients with chronic pain have used different ketamine applications for longer time periods. This experience may be relevant for psychiatric
indications.
Aims
To review the literature about the dosing regimen, duration, effects and side-effects of oral, intravenous, intranasal and subcutaneous routes of administration of ketamine for treatment-resistant depression and pain.
Method
Searches in PubMed with the terms ‘oral ketamine’, ‘depression’, ‘chronic pain’, ‘neuropathic pain’, ‘intravenous ketamine’, ‘intranasal ketamine’ and ‘subcutaneous ketamine’ yielded 88 articles. We reviewed all papers for information about dosing regimen, number of individuals who received ketamine, number of ketamine days per study, results and side-effects, as well as study quality.

Results
Overall, the methodological strength of studies investigating the antidepressant effects of ketamine was considered low, regardless of the route of administration. The doses for
depression were in the lower range compared with studies that investigated analgesic use. Studies on pain suggested that oral ketamine may be acceptable for treatment-resistant
depression in terms of tolerability and side-effects.

Conclusions
Oral ketamine, given for longer time periods in the described doses, appears to be well tolerated, but few studies have systematically examined the longer-term negative
consequences. The short- and longer-term depression outcomes as well as side-effects need


 

Vortrag 2014 :